The event: Phase II study of CYT387 in myelofibrosis.
The timeline: Data at the American Society of Hematology (ASH) annual meeting, Dec. 10-13, 2011. An early peek at the CYT387 data could come in early November when ASH releases research abstracts for its annual meeting.
The stakes: YM BioSciences suffers from a credibility deficit. The company believes CYT387 is a best-in-class drug for myelofibrosis, capable of shrinking enlarged spleens, and most importantly reducing anemia without causing too many harmful side effects. Investors and potential partners want to see more data on CYT387 before they buy into YM Bioscience's story, which makes the ongoing phase II study critical for the company's future.
10 Biotech Trades for Second Half of 2011
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.